Galderma Launches First OBT-Based Restylane Injectables in Japan
Galderma has launched Restylane Defyne and Restylane Refyne in Japan, marking the first authorization of hyaluronic acid injectables powered by its proprietary Optimal Balance Technology (OBT) in the country.
Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026
Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.
ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis
FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.
IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results
IOL Chemicals and Pharmaceuticals reported strong Q3 and nine-month FY26 results, with profit before exceptional items rising 39 percent year-on-year, supported by margin expansion and improved operational performance.
Sanofi Completes Acquisition of Dynavax, Expands Adult Vaccine Portfolio with HEPLISAV-B
Sanofi has finalised its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to strengthen its global adult immunisation business.
Fujifilm Opens GBP 400 Million UK Biomanufacturing Expansion
Backed by an investment of approximately GBP 400 million from Fujifilm Corporation, the development includes the launch of what the company describes as the UK’s largest single-use biopharmaceutical contract development and manufacturing facility.
Novo Nordisk Plans Wegovy Vial Launch to Expand Obesity Care Options
Danish drugmaker Novo Nordisk is planning to introduce vial presentations of its blockbuster obesity treatment Wegovy (semaglutide), expanding the range of delivery formats available for the therapy as competition intensifies in the weight-management market.
NPPA Directs Drugmakers to Revise MRPs After 2026 Duty Exemptions
The National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturers to revise the maximum retail prices (MRP) of medicines that received customs duty exemptions under the Union Budget 2026.
WuXi Vaccines Receives Brazil's ANVISA GMP Certification
Based on the commercial manufacturing agreement with Instituto Butantan and Fundação Butantan, WuXi Vaccines will provide end-to-end services including drug substance and drug product manufacturing and quality control.
Pfizer Joins BaseLaunch Biotech Incubator
Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy